Long-term survival outcomes of lorlatinib in advanced anaplastic lymphoma kinase (ALK)-fusion positive non-small cell lung cancer.

ABSTRACT:

SUBMITTER: Morise M 

PROVIDER: S-EPMC12432676 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature